The risk of early and late CMV DNAemia associated with Campath use in stem cell transplant recipients

The risks associated with in vivo and ex vivo use of Campath-1H and -1G in a cohort of 206 stem cell transplant recipients for human CMV (HCMV) DNAemia have been quantified. DNAemia showed a biphasic incidence pattern with an inflexion at day 60. The first phase had a linear risk rate for HCMV DNAem...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Bone marrow transplantation (Basingstoke) 2010-07, Vol.45 (7), p.1212-1219
Hauptverfasser:	Buyck, H C, Prentice, H G F, Griffiths, P D, Emery, V C
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Alemtuzumab Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal, Humanized Antibodies, Neoplasm - adverse effects Antineoplastic Agents Biological and medical sciences Bone marrow Bone marrow, stem cells transplantation. Graft versus host reaction CD34 antigen Cell Biology Child Child, Preschool Cohort Studies Cytomegalovirus - isolation & purification Cytomegalovirus infections Cytomegalovirus Infections - chemically induced DNA, Viral - blood Drug therapy Female Genetic aspects Graft-versus-host reaction Health aspects Hematology Hematopoietic Stem Cell Transplantation - adverse effects Hematopoietic Stem Cell Transplantation - methods Humans Immune response In Vitro Techniques Internal Medicine Medical sciences Medicine Medicine & Public Health Middle Aged Multivariate Analysis original-article Public Health Radiation therapy Retrospective Studies Risk Risk analysis Risk Factors Stem cell transplantation Stem Cells Time Factors Transfusions. Complications. Transfusion reactions. Cell and gene therapy Transplantation Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!